BioLife Solutions Inc (NASDAQ:BLFS) has earned an average recommendation of “Buy” from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $17.25.

Several research firms have commented on BLFS. Zacks Investment Research downgraded ExlService from a “hold” rating to a “sell” rating in a report on Wednesday, July 10th. Northland Securities boosted their target price on Paycom Software from $215.00 to $275.00 and gave the stock an “outperform” rating in a report on Tuesday, July 9th. BidaskClub downgraded Weyco Group from a “sell” rating to a “strong sell” rating in a report on Saturday. Maxim Group set a $24.00 target price on BioLife Solutions and gave the stock a “buy” rating in a report on Wednesday, May 22nd. Finally, ValuEngine raised XCel Brands from a “sell” rating to a “hold” rating in a report on Tuesday, July 9th.

In other news, CFO Greef Roderick De sold 10,000 shares of the company’s stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $16.09, for a total transaction of $160,900.00. Following the transaction, the chief financial officer now directly owns 35,859 shares of the company’s stock, valued at $576,971.31. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP James Mathers sold 2,500 shares of the company’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $17.15, for a total value of $42,875.00. Following the transaction, the vice president now directly owns 19,884 shares in the company, valued at $341,010.60. The disclosure for this sale can be found here. Insiders sold 213,871 shares of company stock worth $3,773,339 over the last three months. Corporate insiders own 27.00% of the company’s stock.

Large investors have recently made changes to their positions in the company. Cowen Prime Services LLC bought a new position in shares of BioLife Solutions during the first quarter valued at $63,000. Signaturefd LLC bought a new position in shares of BioLife Solutions during the first quarter valued at $161,000. Conestoga Capital Advisors LLC bought a new position in shares of BioLife Solutions during the first quarter valued at $238,000. Spears Abacus Advisors LLC bought a new position in shares of BioLife Solutions during the first quarter valued at $243,000. Finally, GSA Capital Partners LLP lifted its holdings in shares of BioLife Solutions by 21.1% during the fourth quarter. GSA Capital Partners LLP now owns 13,800 shares of the medical equipment provider’s stock valued at $166,000 after purchasing an additional 2,400 shares in the last quarter. 45.79% of the stock is currently owned by hedge funds and other institutional investors.

BLFS stock traded down $0.71 during midday trading on Wednesday, hitting $16.22. The stock had a trading volume of 5,493 shares, compared to its average volume of 247,764. The stock has a market cap of $314.34 million, a price-to-earnings ratio of 116.14 and a beta of 1.32. The stock’s 50-day moving average price is $17.22. BioLife Solutions has a 52-week low of $9.15 and a 52-week high of $26.35. The company has a current ratio of 14.50, a quick ratio of 12.99 and a debt-to-equity ratio of 0.02.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Thursday, May 9th. The medical equipment provider reported $0.03 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.03. The company had revenue of $5.77 million for the quarter, compared to analysts’ expectations of $5.67 million. BioLife Solutions had a return on equity of 10.32% and a net margin of 17.01%. Equities research analysts expect that BioLife Solutions will post 0.12 EPS for the current year.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Recommended Story: Why are gap-down stocks important?

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.